A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease

PHASE3RecruitingINTERVENTIONAL

Enrollment

348

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

April 30, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

Rotigotine 4Mg/24Hrs Patch

Rotigotine 4 mg/24Hrs administration for 24 weeks

DRUG

Placebo

Placebo administration for 24 weeks

Trial Locations (1)

RECRUITING

Santa Lucia Foundation, Rome

All Listed Sponsors

lead

I.R.C.C.S. Fondazione Santa Lucia

OTHER